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Abstract
Background: The cholinergic anti-inﬂammatory pathway (CAP) modulates inﬂammatory responses through the vagus nerve
and the α-7-nicotinic acetylcholine receptor (α7nAChR) on macrophages and immune cells. Sympathetic/parasympathetic
imbalance and chronic inﬂammation are both linked to poor outcome in dialysis patients. The aim of this study was to
investigate CAP activity in these patients.
Methods: Twenty dialysis patients, 12 hemodialysis (HD) and 8 peritoneal dialysis (PD) patients (12 male, 8 female; age range
47–83 years) and 8 controls (5 male, 3 female; age range 31–52 years) were analyzed for C-reactive protein (CRP), tumor necrosis
factor (TNF), interleukin-1b (IL-1b), IL-6 and IL-10 at baseline. The cytokines were then assessed after whole blood stimulation ex
vivo with lipopolysaccharide (LPS) (10 and 100 ng/mL) and again in the presence of 45 and 90 μmol/L GTS-21, a cholinergic
α7nAChR agonist.
Results: CRP, TNF, IL-1 and IL-6 were signiﬁcantly higher, whereas IL-10 was signiﬁcantly lower at baseline in patients
compared with controls. After LPS stimulation, TNF increased signiﬁcantly more in patients than in controls but decreased to
similar levels in both groups after addition of GTS-21. IL-6 attenuation was comparable with TNF and the IL-1b pattern was
similar but remained signiﬁcantly higher in patients. Interestingly, IL-10 increased after GTS-21 in a dose-dependent manner,
but only in patients. Results in HD and PD patients did not differ.
Conclusions: The response of immune cells after LPS exposure and cholinergic stimulation suggests a functional CAP in
dialysis patients. It may thus be possible to target the α7nAChR control of cytokine release as an anti-inﬂammatory strategy and
thereby improve outcome in these patients.
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Introduction

Materials and Methods

The autonomic nervous system controls in part the innate
immune system through the cholinergic anti-inﬂammatory
pathway (CAP). The current understanding of this pathway is
that it operates as a nerve-mediated reﬂex that, in case of injury,
inﬂammation or infection in the periphery, transmits signals to
the central nervous system via the sensory afferent vagus
nerve. The motor ﬁbers in the efferent vagus nerve then activate
the adrenergic splenic nerve, which releases norepinephrine in
the spleen. Acetylcholine-synthesizing T-cells in the spleen located in the proximity of catecholaminergic nerve endings,
which are necessary for attenuation of inﬂammation, have recently been identiﬁed. These specialized T-cells respond to the
norepinephrine signal and release acetylcholine, which modulates cytokine responses by activating α-7-nicotinic acetylcholine
receptors (α7nAChR) on macrophages and other immune cells [1–
5].
Renal impairment entails the loss of several bodily functions
and is an independent risk factor for cardiovascular events, 10- to
20-fold higher than the general population [6]. It has been shown
that dialysis patients have elevated circulating levels of inﬂammatory markers such as CRP, TNF, IL-6 and HMGB1, the latter
identiﬁed as a prototypic alarmin [7–9]. Several of these cytokines
are associated with poor prognosis in this immunocompromised
population [7, 8].
Autonomic dysfunction has been associated with adverse
outcome in a number of clinical conditions, including cardiovascular disease (CVD), congestive heart failure and septicemia
[10–12]. Chronic inﬂammatory diseases such as rheumatoid
arthritis (RA) and systemic lupus erythematosus are associated
with autonomic dysfunction and a reduction in vagus nerve activity [13, 14]. This can be assessed with electrocardiogram
(ECG) measurements by analyzing the heart rate variability
(HRV), which provides a bedside non-invasive method for investigating the autonomic input into the heart or the balance
of the sympathetic and parasympathetic (vagus) nervous systems. The HRV method quantiﬁes the amount by which the
RR interval or heart rate changes between heart beat cycles
and is typically analyzed in relation to time or frequency.
HRV can be measured by continuous electrocardiography over
a 24-h period, but shorter recordings can also be utilized.
In healthy individuals, the rate of beat-to-beat variability is
signiﬁcantly higher than in subjects with autonomic dysfunction. The high-frequency (HF) range (0.15–0.50 Hz) has been
linked to cardiac parasympathetic regulation, reﬂecting vagus
nerve tone. The low-frequency (LF) range (0.04–0.15 Hz) reﬂects
mixed parasympathetic and sympathetic contributions, and
the LF/HF ratio is considered a measurement of sympathovagal
balance [15, 16]. In dialysis patients, autonomic dysfunction is
common and has been associated with poor prognosis. It has
been proposed that HRV may be used as a surrogate marker
for sudden cardiac death in these patients [17, 18]. It has been
hypothesized that CAP can be stimulated either by drugs or by
vagus nerve stimulation (VNS) and thereby inﬂuence the course
of disease by reducing inﬂammation. Preclinical studies in sepsis models and animal models of mice with collagen-induced
arthritis and ischaemia-reperfusion injury have demonstrated
the efﬁcacy of cholinergic agonists as well as VNS [19–22].
There are no previous studies on cholinergic function in patients with chronic kidney disease (CKD). Our aim in this exploratory study was therefore to investigate possible deﬁciencies in
the CAP in CKD patients with autonomic dysfunction treated
with hemodialysis (HD) and peritoneal dialysis (PD).

Patients
The study population consisted of 20 subjects: 12 HD patients
(7 male, 5 female; age range 26–84 years), 8 PD patients (5 male,
3 female; age range 47–84 years) and 8 healthy controls (5 male,
3 female; age range 31–52 years). The patients were recruited
among stable chronic dialysis patients at the Renal Department
at Karolinska University Hospital. Patients on HD were treated
three times per week on average 4 h per dialysis session, whereas
PD patients were treated with a continuous ambulatory PD
(CAPD) regimen, except two who used automated PD (APD). Patients with signs of clinical infection were excluded from the
study. Healthy controls were recruited among the staff of the
Renal Department. A summary of patient characteristics including age, gender, dialysis modality and time on dialysis is found in
Table 1.
The study protocol was approved by the local ethics committee and informed consent was obtained from each subject.

Methods
All subjects were sampled in the morning. HD patients were
sampled on a dialysis day prior to dialysis treatment. Blood samples were analyzed for C-reactive protein (CRP), hemoglobin (Hb),
white blood cell count (WBC) with differentials, tumor necrosis
factor (TNF), interleukin-1b (IL-1b), IL-6 and IL-10 at baseline.
CRP, Hb and WBC were analyzed using routine methods at the
Department of Clinical Chemistry at Karolinska University
Hospital.

Ex vivo whole blood assay
The whole blood assay was performed by a method previously
described [23]. Brieﬂy, whole blood samples were stimulated ex
vivo with two concentrations of lipopolysaccharide (LPS) (10 and
100 ng/mL) to induce an inﬂammatory reaction. TNF, IL-1b, IL-6
and IL-10 were measured at these concentrations and again in
the presence of 45 and 90 μmol/L GTS-21, a selective α7nAChR
cholinergic agonist.

Table 1. Clinical and biochemical characteristics of dialysis patients
and healthy controls
Patients (n = 20)
Sex female (%)
Age (years)
Time on dialysis
(months)
CRP (mg/L)
B-Hb (g/L)
B-WBC, 109
B-monocytes
B-lymphocytes
TNF ( pg/mL)a
IL-1b ( pg/mL)a
IL-6 ( pg/mL)a
IL-10 ( pg/mL)a

42
65 (47–83)
27 (2–91)
5 (0.3–22.6)
113 (99–136)
7.8 (4.4–10.6)
0.7 (0.3–1.35)
1.5 (0.9–2.2)
33 (16.5–49.7)
1.6 (1.3–8.8)
7.9 (4.2–15.6)
3.9 (2.8–4.8)

Controls (n = 8) P-value
38
46 (31–52)
NA

0.92
0.002

0.0 (0.0–8)
137 (121–154)
5.1 (3.8–10.7)
0.5 (0.4–0.9)
1.9 (1.2–3.1)
10.1 (7.3–22.2)
2.7 (0.2–9.3)
0.9 (0.2–8.8)
4.6 (2.5–16.4)

0.004
0.0006
0.08
0.13
0.16
0.001
0.02
0.002
0.002

Data are expressed as median and (10–90) percentiles. References CRP, Hb and so
on <3 mg/L; B-Hb 117–153 g/L (female), 134–170 g/L (male); B-white blood cell
count (WBC) 3.5–8.8 × 109/L; B-monocytes 0.1–1.0 × 109/L; and B-lymphocytes
1.0–4.0 × 109/L. NA, not applicable.
a

Baseline values prior to LPS stimulation.
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Whole blood was collected in two heparinized tubes and immediately kept in a 37°C heated container until processed within
60–120 min.
LPS from Escherichia coli 0111:B4 was obtained from SigmaAldrich (St Louise, MO, USA; cat. no. L4130). Five milligrams of LPS
was dissolved in 1 mL phosphate-buffered saline (PBS), sonicated
for 30 min, vortexed well and diluted ﬁve times to 1 × 106 ng/mL
(=stock solution) and then portioned and frozen at −80°C.
Solutions of GTS-21 and LPS were prepared as follows. The
1 × 106 ng/mL stock solution of LPS was serially diluted with PBS
to 10 000 and 1000 ng/mL. GTS-21 (2 mg) was diluted in distilled
water to approximately 4.6 and 9.2 mmol/L working solutions,
respectively.
One milliliter each of whole blood was pipetted into twelve 2mL Eppendorf tubes. Ten microliters of PBS was added to tubes
1–4, 10 µL of 4.6 mmol/L GTS-21 working solution (ﬁnal concentration ∼45 µmol/L) to tubes 5–8 and 10 µL of 9.2 mmol/L GTS-21
working solution (ﬁnal concentration ∼90 µmol/L) to tubes 9–12.
The tubes were incubated at 37°C for 15 min on a rocking platform.
Then, 10 µL of PBS was added to tubes 1, 2, 5, 6, 9 and 10; 10 µL of
1000 ng/mL LPS (ﬁnal concentration ∼10 ng/mL) was added to
tubes 3, 7 and 11; and 10 µL of 10 000 ng/mL LPS (ﬁnal concentration ∼100 ng/mL) was added to tubes 4, 8 and 12. (Thus, tubes 1 and
2 containing whole blood and PBS only served as controls.)
After a 4-h incubation at 37°C on a rocking platform, plasma
was collected by centrifugation (2600g, 20 min, 18°C, Eppendorf
centrifuge 5804R) and frozen at −80°C pending cytokine analyses.

Cytokine analysis
High-sensitivity TNF, IL-1b, IL-6 and IL-10 were analyzed by
immunometric assays on an Immulite 1000 Analyzer (Siemens
Healthcare Diagnostics, Los Angeles, CA, USA) according to the
instructions of the manufacturer.

Heart rate variability
HRV was measured in a subset of dialysis patients and in all the
controls. These measurements were, due to practical reasons,
not done at blood sampling but at a separate visit. Twelve patients (seven on HD, ﬁve on PD and the eight healthy control subjects) were assessed for HRV, which was done in a quiet
examining room in a supine position.
ECG and tetrapolar thoracic bioimpedance were measured
over 20 min using a custom-made device, designed by Z-Health
Technologies (Borås, Sweden). By this method, the RR interval
variability (RRV) is automatically calculated based on the Pan–
Tompkins algorithm [24]. Artifacts and ectopic beats were detected and removed visually (<2% of beats were removed). Thoracic bioimpedance measurements were used to calculate
respiration rate. The HRV analysis generated data for time and
frequency domain parameters according to the European Society
of Cardiology Task Force for HRV measurements [15]. The time
domain parameter standard deviation of normal-to-normal intervals (SDNN) was recorded as an overall estimate of HRV, and
frequency domain was recorded as LF and HF and the LF/HF
ratio. Respiration rate and heart rate were also measured.

Statistical methods
All values are expressed as median (10th, 90th percentile) or percentage as appropriate according to the type and distribution of
the data. P-values <0.05 were considered statistically signiﬁcant.
Comparisons between groups were performed using non-parametric Wilcoxon’s test. Comparisons between groups and
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various concentrations of LPS were performed using Friedman’s
non-parametric two-way ANOVA. Fischer’s exact test and chisquare test were used for categorical variables. Non-parametric
Spearman’s rank correlation analysis was used to determine associations between various variables. As P-values are not adjusted for multiple testing, they have to be considered as
descriptive. All statistical analyses were performed using SAS
version 9.4 (SAS Institute, Cary, NC, USA).

Results
There was a signiﬁcant difference in age between patients and
controls but not in gender (Table 1).
There were no signiﬁcant differences for HRV in the HD and PD
groups (data not shown), and hence the results of all dialysis patients were compared with controls. The result of HRV analysis
conﬁrmed signiﬁcant autonomic dysfunction in patients when
compared with controls with regard to the time domain parameter
SDNN as well as the frequency domain parameters HF and LF
(Table 2 and Figure 1A–C). Respiration rate and heart rate did not
differ between groups. However, one HD patient with high heart
and respiratory rates was excluded from the analysis as an outlier.
TNF, IL-1b, IL-6, IL-10 and CRP were signiﬁcantly increased at
baseline in patients compared with controls (Table 1). After LPS
stimulation ex vivo at the two concentrations (10 and 100 ng/
mL), there was an increase of TNF, with a signiﬁcantly stronger
augmentation in patients at maximal stimulation compared
with controls. In the presence of GTS-21, there was a robust decrease in TNF levels in patients, which did not differ signiﬁcantly
from controls (Figure 2A–C). There was no difference in TNF levels
after LPS exposure or in the presence of GTS-21 between HD and
PD patients (data not shown), and the cytokine data are therefore
reported as all dialysis patients compared with controls.
IL-1b was signiﬁcantly increased in patients at the two LPS
concentrations compared with controls. In both groups, IL-1b
decreased in the presence of GTS-21, but a statistical difference
remained between groups, with higher levels in patients
(Figure 3A–C). The IL-6 pattern was similar to TNF at maximal
stimulation with LPS, but again with comparable cytokine
suppression with GTS-21 in both groups (Figure 4A–C). Finally,
IL-10 representing an anti-inﬂammatory cytokine increased in
the presence of GTS-21 in a dose-dependent manner, but only
in patients (Figure 5A–C).
Total WBC and differentials did not differ between groups.

Discussion
Increased morbidity and mortality in CKD remains a major challenge [7, 8]. Approximately one-third of deaths among dialysis
Table 2. Clinical and HRV parameters of healthy subjects and dialysis
patients
Controls (n = 8)

Patients (n = 11) P-value

Age (years)
46 (31–52)
66 (31–82)
1289 (56–3489)
83 (36–529)
LF (ms2)
HF (ms2)
449 (49–2393) 106 (8–248)
LF/HF ratio
2.2 (0.9–6.7)
2.2 (0.3–7.1)
SDNN (ms)
39.3 (17.1–70.2) 16 (9.8–48.8)
Heart rate (beats/min)
62 (48–84)
70 (65–125)
Respiration (breaths/min)
16 (13–18)
15 (11–19)

0.003
0.005
0.02
0.56
0.047
0.06
0.90

Data are expressed as median and (10–90) percentiles.
LF, low-frequency; HF, high-frequency; SDNN, standard deviation of normal-tonormal intervals.
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Fig. 2. TNF levels (A) after LPS: 0, 10 and 100 ng/mL; (B) after GTS-21: 45 μmol/L; and
(C) 90 μmol/L in dialysis patients and controls. **P < 0.01. All samples except basal
incubated for 4 h.
Fig. 1. (A) High-frequency (HF) power in patients and controls. (B) LF power in
patients and controls. (C) Relationship of HF and LF powers of HRV for controls
and patients HF (y-axis) versus LF (x-axis) with logarithmic scale.

patients may be attributable to autonomic nervous system dysfunction [25]. Increased sympathetic activity is also noted in patients with chronic renal failure prior to dialysis and has been
shown to contribute to the increased risk of CVD and possibly
also to renal damage [26, 27]. Although identiﬁed as a possible
modiﬁable target, most of the focus in this research ﬁeld has
been on increased sympathetic activity and less on parasympathetic or vagus activity.
HRV is a non-invasive measure of autonomic function. It has
repeatedly been shown that decreased HRV can be predictive of
survival in the CKD population [17, 18, 25–30]. In this study we
found that our cohort did not differ from previously studied dialysis patients.
A state of chronic inﬂammation affects outcome and is a
strong prognostic factor of sudden death in end-stage renal

disease patients [7, 31]. Treatment of this persistent condition
may therefore be beneﬁcial in reducing morbidity and mortality.
Thus far, the effect of various anti-inﬂammatory interventions
on outcome has yet to be proved in this patient population [32].
In the current study we investigated whether immune cells
from dialysis patients with autonomic dysfunction were able to
react in a functional way ex vivo with cytokine attenuation after
endotoxin exposure with LPS and cholinergic suppression. We
demonstrated that inﬂammatory cells from dialysis patients exposed to an environment of autonomic dysfunction with decreased vagus nerve activity in vivo respond to cholinergic
agonists ex vivo in a similar manner compared with healthy controls, suggesting a functional CAP. We were surprised that there
were no differences between HD and PD patients. Dialysis ﬁlters
used in HD may trigger inﬂammation in addition to the underlying inﬂammatory dysregulation common in most dialysis patients. On the other hand, chronic ﬂuid overload in PD patients
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Fig. 4. IL-6 levels (A) after LPS: 0, 10 and 100 ng/mL; (B) after GTS-21: 45 μmol/L; and
(C) 90 μmol/L in dialysis patients and controls. **P < 0.01. All samples except basal
incubated for 4 h.

Fig. 3. IL-1b levels (A) after LPS: 0, 10 and 100 ng/mL; (B) after GTS-21: 45 μmol/L;
and (C) 90 μmol/L in dialysis patients and controls. **P < 0.01. All samples except
basal incubated for 4 h.

contributes to inadequate blood pressure control and left ventricular hypertrophy, which may increase inﬂammation as
shown in a recent study [33]. However, our data suggest that it
is the end-stage renal disease and dialysis dependency that is important rather than dialysis modality for cytokine expression in
this model.
The major limitations of this study were the relatively small
sample size and that patients and controls were sampled only
once. However, in a similarly designed study of RA patients
who came for one to eight visits, we could not ﬁnd any signiﬁcant
difference in HRV and whole blood assay results at repeated visits. This suggests that the combined phenotype of autonomic
dysfunction and the innate response to endotoxin stimulation
with LPS in chronic inﬂammation is fairly stable. Interestingly,
dialysis patients differed from RA patients by having a much

stronger inﬂammatory response to LPS in the whole blood
model [23]. This may reﬂect that the RA patients were treated
with anti-inﬂammatory drugs, which was not the case with the
dialysis patients, or possibly that there is an inherent biological
difference between RA and CKD. However, the response to the
cholinergic agonist was similar, suggesting a functional CAP
irrespective of underlying disease. Another issue was that the control population was signiﬁcantly younger compared with dialysis
patients, which could potentially be important since HRV is
known to decrease with age [15, 16]. However, in spite of signiﬁcant differences in HRV, the response to the cholinergic agonist
did not differ between groups in the current study. Finally, it
may also be argued that the ex vivo situation with GTS-21 does
not fully represent the in vivo biology. However, GTS-21 has been
proved effective as an immunomodulatory compound by attenuating pro-inﬂammatory cytokine levels and improving survival in
sepsis models [22, 34].
Since the discovery of the CAP, preclinical studies have demonstrated the effect of cholinergic agonists and VNS in sepsis,
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after cholinergic stimulation. To the best of our knowledge,
these are novel ﬁndings in this patient population and may be
worth exploring in the evolving therapeutic ﬁeld of neuroimmunomodulation by cholinergic modalities.
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